UNSPSC 51431905: Exaprolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FGT82HNC7L, chemically known as 2-propanol, 1-(2-cyclohexylphenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (+-)- but more generally known as exaprolol hydrochloride, which bears US NIH Compound Identifier 65484. Most nations, for tariff and trade purposes, schedule exaprolol hydrochloride under HS 29221980 and SITC 51461.

As of Q4 2014, EXAPROLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Exaprolol hydrochloride bears US NLM identifiers UMLS ID C0952592 and NCI Concept Code C65610. SMILES: CC(C)NCC(COC1CCCCC1C2CCCCC2)O.CL.

UNSPSC 51431905 Exaprolol hydrochloride is a Commodity code that does not align with the state and local procurement opportunities posted under it. The recent solicitations tag generic pharmaceuticals, OTC products, and emergency medications broadly—labetalol, epinephrine, adenosine, and diltiazem—but none specifically reference exaprolol hydrochloride, a beta-blocker no longer commonly manufactured or stocked in U.S. pharmacies. The mismatch suggests either a data-classification artifact or dormant procurement activity under this code.

State and local agencies purchasing under this code area include municipal fire departments, state health agencies, and cooperative purchasing consortia serving multistate membership. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications supplying Tampa Fire Rescue with four emergency-response drugs through a one-year term with renewal options; estimated value was $40,000.00, with a 5 percent SLBE bid discount capped at $10,000. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription contracting outside traditional PBM and GPO channels, signaling state interest in alternative pharmaceutical supply models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating states including Oregon, with contract effective July 1, 2026, requiring cGMP and DSCSA compliance and contractual relationships with authorized wholesalers AmerisourceBergen (Cencora), Cardinal Health, or Morris & Dickson. Activity concentrates in Texas, Minnesota, and Florida; no recent opportunities support procurement of exaprolol hydrochloride specifically, marking the code as effectively dormant under current state and local demand.